The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer : a systematic review and meta-analysis
BACKGROUND: The purpose of this study was to explore the efficacy and tolerability of poly ADP-ribose polymerase (PARP) inhibitors in patients with ovarian cancer.
METHODS: The meta-analysis searched the PubMed, Web of Science, EBSCO, and Cochrane libraries from inception to February 2020 to identify relevant studies. And the main results of this study were long-term prognosis and treatment-related adverse events.
RESULTS: The results showed that the addition of PARP inhibitors could significantly prolong progression-free survival (PFS) and overall survival (OS) for patients with ovarian cancer (HR 0.44, 95% CI 0.34-0.53, p < 0.001; HR, 0.79, 95% CI 0.65-0.94, p < 0.001, respectively). In the BRCA 1/2 mutation patients, the HR of PFS was 0.29 (p < 0.001), and the HR was 0.51 (p < 0.001) in the no BRCA 1/2 mutation patients. The HR of PFS was 0.40 (p < 0.001) in the homologous recombination deficiency (HRD) mutation patients, while the HR was 0.80 (p < 0.001) in the no HRD mutation patients. Moreover, the analysis found that the use of PARP inhibitors did not significantly increase the risk of all grade adverse events (AEs) (RR = 1.04, p = 0.16). But the incidence of grade 3 or higher AEs was increased (RR = 1.87, p = 0.002). In general, the AEs were mainly manifested in the blood system.
CONCLUSIONS: PARP inhibitors can improve the prognosis of ovarian cancer patients with and without genetic mutations (BRCA 1/2 or HRD). Furthermore, PARP inhibitors were tolerable to patients when added to their current therapy, although it inevitably adds the grade 3 and higher AEs.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
World journal of surgical oncology - 18(2020), 1 vom: 04. Juli, Seite 151 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Yang, Yingzhu [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1186/s12957-020-01931-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312000766 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312000766 | ||
003 | DE-627 | ||
005 | 20231225143450.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12957-020-01931-7 |2 doi | |
028 | 5 | 2 | |a pubmed24n1039.xml |
035 | |a (DE-627)NLM312000766 | ||
035 | |a (NLM)32622363 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Yang, Yingzhu |e verfasserin |4 aut | |
245 | 1 | 4 | |a The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer |b a systematic review and meta-analysis |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2021 | ||
500 | |a Date Revised 14.05.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: The purpose of this study was to explore the efficacy and tolerability of poly ADP-ribose polymerase (PARP) inhibitors in patients with ovarian cancer | ||
520 | |a METHODS: The meta-analysis searched the PubMed, Web of Science, EBSCO, and Cochrane libraries from inception to February 2020 to identify relevant studies. And the main results of this study were long-term prognosis and treatment-related adverse events | ||
520 | |a RESULTS: The results showed that the addition of PARP inhibitors could significantly prolong progression-free survival (PFS) and overall survival (OS) for patients with ovarian cancer (HR 0.44, 95% CI 0.34-0.53, p < 0.001; HR, 0.79, 95% CI 0.65-0.94, p < 0.001, respectively). In the BRCA 1/2 mutation patients, the HR of PFS was 0.29 (p < 0.001), and the HR was 0.51 (p < 0.001) in the no BRCA 1/2 mutation patients. The HR of PFS was 0.40 (p < 0.001) in the homologous recombination deficiency (HRD) mutation patients, while the HR was 0.80 (p < 0.001) in the no HRD mutation patients. Moreover, the analysis found that the use of PARP inhibitors did not significantly increase the risk of all grade adverse events (AEs) (RR = 1.04, p = 0.16). But the incidence of grade 3 or higher AEs was increased (RR = 1.87, p = 0.002). In general, the AEs were mainly manifested in the blood system | ||
520 | |a CONCLUSIONS: PARP inhibitors can improve the prognosis of ovarian cancer patients with and without genetic mutations (BRCA 1/2 or HRD). Furthermore, PARP inhibitors were tolerable to patients when added to their current therapy, although it inevitably adds the grade 3 and higher AEs | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Review | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a BRCA 1/2 | |
650 | 4 | |a HRD | |
650 | 4 | |a Meta-analysis | |
650 | 4 | |a Ovarian cancer | |
650 | 4 | |a PARP inhibitor | |
650 | 7 | |a Poly(ADP-ribose) Polymerase Inhibitors |2 NLM | |
650 | 7 | |a Adenosine Diphosphate Ribose |2 NLM | |
650 | 7 | |a 20762-30-5 |2 NLM | |
650 | 7 | |a Poly(ADP-ribose) Polymerases |2 NLM | |
650 | 7 | |a EC 2.4.2.30 |2 NLM | |
700 | 1 | |a Du, Nannan |e verfasserin |4 aut | |
700 | 1 | |a Xie, Laidi |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Jing |e verfasserin |4 aut | |
700 | 1 | |a Mo, Jiahang |e verfasserin |4 aut | |
700 | 1 | |a Hong, Jiaze |e verfasserin |4 aut | |
700 | 1 | |a Mao, Danyi |e verfasserin |4 aut | |
700 | 1 | |a Ng, Derry Minyao |e verfasserin |4 aut | |
700 | 1 | |a Shi, Huiwei |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t World journal of surgical oncology |d 2003 |g 18(2020), 1 vom: 04. Juli, Seite 151 |w (DE-627)NLM125391404 |x 1477-7819 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2020 |g number:1 |g day:04 |g month:07 |g pages:151 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12957-020-01931-7 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2020 |e 1 |b 04 |c 07 |h 151 |